Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models

Liver Transplantation

Volumn 14, Issue 12, 2008, Pages 1737-1744

  Farmer, Douglas G ^a,c   Kaldas, Fady ^a   Anselmo, Dean ^a   Katori, Masamichi ^a   Shen, Xiu Da ^a   Lassman, Charles ^a   Kaldas, Marian ^a   Clozel, Martine ^b   Busuttil, Ronald W ^a   Kupiec Weglinski, Jerzy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ACTELION PHARMACEUTICALS LTD   (Switzerland)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILE ACID; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN; PURINE NUCLEOSIDE PHOSPHORYLASE; SODIUM CHLORIDE; TEZOSENTAN; ENDOTHELIN RECEPTOR; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM INJURY; EX VIVO STUDY; HEMODYNAMICS; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; ISOGRAFT; LIVER CELL DAMAGE; LIVER INJURY; LIVER ISCHEMIA; LIVER SINUSOID; LIVER TRANSPLANTATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SURVIVAL RATE; TISSUE OXYGENATION; VASCULAR RESISTANCE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ISCHEMIA; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; DISEASE MODELS, ANIMAL; HEMODYNAMICS; ISCHEMIA; LIVER; LIVER TRANSPLANTATION; MALE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; REPERFUSION INJURY; TETRAZOLES; WARM ISCHEMIA;

EID: 58249089660     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21621     Document Type: Article

References (34)

1. Farmer DG, Amersi F, Kupiec-Weglinski JW, Busuttil RW. Current status of ischemia and reperfusion injury in the liver. Transplant Rev 2000;14:106-126.
2. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988;6:S188-S191.
3. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T. Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
4. Goto M, Takei Y, Kawano S, Nagano K, Tsuji S, Masuda E, et al. Endothelin-1 is involved in the pathogenesis of ischemia/reperfusion liver injury by hepatic microcirculatory disturbances. Hepatology 1994;19:675-681.
5. Mitsuoka H, Suzuki S, Sakaguchi T, Baba S, Miwa M, Konno H, Nakamura S. Contribution of endothelin-1 to microcirculatory impairment in total hepatic ischemia and reperfusion injury. Transplantation 1999;67:514-520.
6. Zhang JX, Bauer M, Clemens MG. Vessel- and target cell-specific actions of endothelin-1 and endothelin-3 in rat liver. Am J Physiol 1995;269(pt 1):G269-G277.
7. Mustafa SB, Gandhi CR, Harvey SA, Olson MS. Endothelin stimulates platelet-activating factor synthesis by cultured rat Kupffer cells. Hepatology 1995;21:545-553.
8. Zhou W, McCollum MO, Levine BA, Olson MS. Inflammation and platelet-activating factor production during hepatic ischemia/ reperfusion. Hepatology 1992;16:1236-1240.
9. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999;290:840-846.
10. Dingemanse J, Gunawardena KA, van Giersbergen PL. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjects. Br J Clin Pharmacol 2006;61:405-413.
11. Wilhelm SM, Stowe NT, Robinson AV, Schulak JA. The use of the endothelin receptor antagonist, tezosentan, before or after renal ischemia protects renal function. Transplantation 2001;71:211-216.
12. Dulkanchainun TS, Goss JA, Imagawa DK, Shaw GD, Anselmo DM, Kaldas F, et al. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. Ann Surg 1998;227:832-840.
13. Amersi F, Buelow R, Kato H, Ke B, Coito AJ, Shen XD, et al. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest 1999;104:1631-1639.
14. Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979;28:47-50.
15. Rao PN, Walsh TR, Makowka L, Rubin RS, Weber T, Snyder JT, Starzl TE. Purine nucleoside phosphorylase: a new marker for free oxygen radical injury to the endothelial cell. Hepatology 1990;11:193-198.
16. Hoffee PA, May R, Robertson BD. Purine nucleoside phosphorylase from Salmonella typhimurium and rat liver. Methods Enzymol 1978;51:517-524.
17. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993;55:1265-1272.
18. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991; 88:1054-1057.
19. Zhang XY, Francis RJ, Sun CK, Wheatley AM. Endothelin receptor A blockade ameliorates hypothermic ischemia-reperfusion-related microhemodynamic disturbances during liver transplantation in the rat. J Surg Res 2002; 102:63-70.
20. Witzigmann H, Ludwig S, Escher E, Armann B, Gabel G, Teupser D, et al. Administration of a selective endothelin-a receptor antagonist (BSF 208075) improves hepatic warm ischemia/reperfusion injury in pigs. Transplant Proc 2002;34:2387-2388.
21. Bauer M, Bauer I, Sonin NV, Kresge N, Baveja R, Yokoyama Y, et al. Functional significance of endothelin B receptors in mediating sinusoidal and extrasinusoidal effects of endothelins in the intact rat liver. Hepatology 2000;31:937-947.
22. Dingemanse J, van Giersbergen PL. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. Br J Clin Pharmacol 2004;57:344-348.
23. van Giersbergen PL, Dingemanse J. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan. Int J Clin Pharmacol Ther 2003;41:261-266.
24. Roux S, Breu V, Ertel SI, Clozel M. Endothelin antagonism with bosentan: a review of potential applications. J Mol Med 1999;77:364-376.
25. Spiegel HU, Uhlmann D, Scommotau S, Giersch B, Sulkowski U. Effect of the endothelin receptor antagonist bosentan on postischemic oxygen supply of the liver. J Invest Surg 1996;9:439-445.
26. Uhlmann D, Uhlmann S, Palmes D, Spiegel HU. Endothelin receptor blockade as a therapeutic strategy in ameliorating postischemic damage to the liver microcirculation. J Cardiovasc Pharmacol 2000;36(suppl 1):S351-S353.
27. Koeppel TA, Kraus T, Thies JC, Gebhard MM, Otto G, Post S. Effects of mixed ETA and ETB-receptor antagonist (Ro-47-0203) on hepatic microcirculation after warm ischemia. Dig Dis Sci 1997;42:1316-1321.
28. Ricciardi R, Schaffer BK, Shah SA, Quarfordt SH, Banner BF, Wheeler SM, et al. Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/ reperfusion injury. J Gastrointest Surg 2001;5:322-329.
29. Kitayama Y, Yamanaka N, Kawamura E, Kuroda N, Okamoto E. Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver. Hepatology 1997;25:938-942.
30. Goto M, Kawano S, Yoshihara H, Takei Y, Hijioka T, Fukui H, et al. Hepatic tissue oxygenation as a predictive indicator of ischemia-reperfusion liver injury. Hepatology 1992;15:432-437.
31. Karwinski W, Husoy AM, Farstad M, Soreide O. Sixty minutes of normothermic ischemia in the rat liver: correlation between adenine nucleotides and bile excretion. J Surg Res 1989;46:99-103.
32. Shirasugi N, Wakabayashi G, Shimazu M, Shito M, Kawachi S, Kitajima M. Interleukin-1 receptor blockade attenuates oxygen-derived free radical production and microcirculatory disturbances in ischemia/reperfusion injury in the liver. Transplant Proc 1997;29:371-373.
33. Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and Kupffer cells. Hepatology 1998;27: 507-512.
34. Lopez-Farre A, Riesco A, Espinosa G, Digiuni E, Cernadas MR, Alvarez V, et al. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation 1993;88:1166-1171.